Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 33.3%Moderate 2 · 66.7%High 0 · 0%

Serious adverse events · people with systemic sclerosis

Autologous myeloablative selective HSCT showed no clear difference in serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 1.43 [0.99, 2.08]
1 study · 71 participants
Moderate

Serious adverse events · people with systemic sclerosis

Autologous non‐myeloablative selective HSCT probably leads to higher serious adverse events compared with cyclophosphamide (moderate certainty).

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
RR 1.7 [1.2, 2.3]
1 study · 156 participants
Moderate

Serious adverse events · people with systemic sclerosis

1 finding from 1 review

Stem cell transplantation for systemic sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
Low